Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Richard Greil

Showing results (281-290 of 483) with videos related to

Pageof 49
Sort By:
Lung Cancer (Amsterdam, Netherlands)|January 8, 2015
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registryFlorian Kocher, Wolfgang Hilbe, Andreas Seeber, et al.
Journal of Clinical Medicine|September 2, 2020
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant ChemoradiotherapyFlorian Huemer, Eckhard Klieser, Daniel Neureiter, et al.
Journal of Clinical Medicine|April 3, 2020
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 RegistryFlorian Huemer, Lukas Weiss, Peter Regitnig, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysisMoritz Müller, Florian Posch, Dominik Kiem, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 13, 2021
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancerKonstantin Schlick, Steiner Markus, Florian Huemer, et al.
Research and Practice in Thrombosis and Haemostasis|October 18, 2024
Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI studyChristian Herbert Burgmann, Ulrich J Sachs, Karolin Trautmann-Grill, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
Pageof 49

Showing results (281-290 of 483) with videos related to

Sort By:
Pageof 49
Lung Cancer (Amsterdam, Netherlands)|January 8, 2015
Longitudinal analysis of 2293 NSCLC patients: a comprehensive study from the TYROL registryFlorian Kocher, Wolfgang Hilbe, Andreas Seeber, et al.
Journal of Clinical Medicine|September 2, 2020
Impact of PD-L1 Scores and Changes on Clinical Outcome in Rectal Cancer Patients Undergoing Neoadjuvant ChemoradiotherapyFlorian Huemer, Eckhard Klieser, Daniel Neureiter, et al.
Journal of Clinical Medicine|April 3, 2020
Local and Central Evaluation of HER2 Positivity and Clinical Outcome in Advanced Gastric and Gastroesophageal Cancer-Results from the AGMT GASTRIC-5 RegistryFlorian Huemer, Lukas Weiss, Peter Regitnig, et al.
Therapeutic Advances in Medical Oncology|October 7, 2021
Benefit of second-line therapy for advanced esophageal squamous cell carcinoma: a tri-center propensity score analysisMoritz Müller, Florian Posch, Dominik Kiem, et al.
The Lancet. Haematology|March 26, 2021
Intensified treatment of patients with early stage, unfavourable Hodgkin lymphoma: long-term follow-up of a randomised, international phase 3 trial of the German Hodgkin Study Group (GHSG HD14)Sarah Gillessen, Annette Plütschow, Michael Fuchs, et al.
Pancreatology : Official Journal of the International Association of Pancreatology (IAP) ... [Et Al.]|September 13, 2021
Evaluation of circulating cell-free KRAS mutational status as a molecular monitoring tool in patients with pancreatic cancerKonstantin Schlick, Steiner Markus, Florian Huemer, et al.
Research and Practice in Thrombosis and Haemostasis|October 18, 2024
Comorbidity and adverse events in acquired hemophilia A: data from the GTH-AHA-EMI studyChristian Herbert Burgmann, Ulrich J Sachs, Karolin Trautmann-Grill, et al.
Oncotarget|April 21, 2015
CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21Sylvia Ganghammer, Evelyn Hutterer, Elisabeth Hinterseer, et al.
Annals of Hematology|June 5, 2018
Fludarabine and rituximab with escalating doses of lenalidomide followed by lenalidomide/rituximab maintenance in previously untreated chronic lymphocytic leukaemia (CLL): the REVLIRIT CLL-5 AGMT phase I/II studyAlexander Egle, Michael Steurer, Thomas Melchardt, et al.
Journal of Thrombosis and Haemostasis : JTH|June 27, 2024
Emicizumab versus immunosuppressive therapy for the management of acquired hemophilia AChristina Hart, Robert Klamroth, Ulrich J Sachs, et al.
Pageof 49